Evidence-based Intervention for Diabetes Prevention (EID)

February 24, 2026 updated by: New York University

The goal of this behavioral intervention trial is to develop strategies to decrease the incidence of diabetes within the UAE. The investigators will investigate the effectiveness of a group-based telehealth intervention facilitated by a health coach in adults at risk for developing diabetes who live in the UAE.

The investigators will conduct a single-arm feasibility trial of the Evidence-based Intervention for Diabetes prevention among thirty adults with prediabetes. All participants will receive 12 weekly virtual intervention sessions over the course of three months, facilitated by a trained DPP lifestyle coach who is from the same cultural community and can deliver the material in either Arabic or English.

The primary feasibility measure is acceptability, as measured by intervention session attendance. Other outcome assessments will be conducted at baseline and three months at NYU Abu Dhabi, where study staff will assess weight, hemoglobin A1c, diet, and physical activity.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Study Purpose This feasibility study will investigate the effectiveness of an individual automated plus group-based telehealth arm facilitated by a health coach. The long-term goal is to develop strategies to decrease the incidence of diabetes within the UAE.

Study Hypotheses Participants will attend >50% of intervention sessions and will experience a clinically significant reduction in weight of 3.5% after 12 weeks. Predictors of intervention acceptability will include age, gender, and baseline body mass index.

Study Objectives Study investigators will conduct a single-arm feasibility trial of the Evidence-based Intervention for Diabetes prevention among thirty adults with prediabetes. All participants will receive 12 weekly virtual intervention sessions over the course of three months, facilitated by a trained DPP lifestyle coach who is from the same cultural community and can deliver the material in either Arabic or English.

The primary feasibility measure is acceptability. Other outcome assessments will be conducted at baseline and three months at NYU Abu Dhabi where study staff will assess weight, hemoglobin A1c, diet, and physical activity.

This project will accomplish the following specific aims:

Aim 1: Identify predictors associated with intervention adherence.

Predictors of adherence to intervention arms will include age, gender, and baseline body mass index.

Predictors of adherence to intervention arms will include age, gender, and baseline body mass index. Investigators will also evaluate the acceptability of the intervention using surveys and semi-structured interviews.

Aim 2: Assess the effectiveness of the intervention on key clinical outcomes.

Hypothesis 2: Participants will experience a clinically significant reduction in weight of 3.5% after 12 weeks. In-person outcome assessment visits to measure weight and glycemia at baseline, and 3 months among all participants will be conducted.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Jeannette Beasley, PhD
  • Phone Number: 646-501-4681
  • Email: jbeasley@nyu.edu

Study Locations

  • United Arab Emirates
      • Abu Dhabi, United Arab Emirates, 129188
        • New York University Abu Dhabi
        • Contact:
          • Andrea L Leinberger-Jabari, MPH
          • Phone Number: 971 2 628 4206
          • Email: aj100@nyu.edu
        • Contact:
          • Youssef Idaghdour, PhD
          • Phone Number: 971 2 628 5332
          • Email: yi3@nyu.edu
        • Principal Investigator:
          • Youssef Idaghdour, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Men and women 18 years or older
  • Diabetes risk score > 5
  • BMI >=25kg/m^2
  • Arabic or English speaking
  • Able to read and write in Arabic or English
  • Access to a smartphone
  • Provide informed consent

Exclusion Criteria:

  • Prevalent diabetes
  • Prior participation in a diabetes prevention program
  • Taking FDA-approved weight loss medications
  • Pregnant or lactating

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group facilitated behavioral counseling arm
Participants in this arm will participate in 12 group counseling sessions online. Sessions will be weekly. The 12 sessions are adapted from the CDC DPP program and will deliver culturally appropriate information on diet and activity to prevent diabetes. The participants will have access to video content and will also receive written curricular materials. All materials are culturally adapted and translated into Arabic. The participants will also have access to a local smartphone app to assist with goal setting, logging physical activity and food intake, as well as receiving additional personalized health recommendations.
Behavioral: Adapted diabetes prevention program

The intervention is based on the CDC Diabetes Prevention Program and has been adapted into a culturally appropriate intervention in an Arab context. The program has been condensed into 12 sessions with an additional session that addresses lifestyle factors during Ramadan. Each session covers a different topic related to diet, physical activity, sleep, and stress management. Additionally, the intervention includes written materials to help participants develop lifestyle goals and encourages them to seek social support. There are a series of 12 videos in Arabic and English that support the information delivered in the group sessions.

In addition to the group sessions, participants will have access to the automated app and education materials.

Behavioral: App based support
This intervention will provide educational videos that have been culturally adapted to the Arab context and additional automated supports for lifestyle modification. Study participants will be provided with access to an app that they will be encouraged to engage with on a regular basis. The app will provide basic diet, physical activity, and lifestyle support to prevent diabetes. Participants will also be able to track activity, diet, and receive feedback on their personal weight, diet habits, and activity levels.
Behavioral: Patient education materials
Participants will be provided written or web-based diabetes prevention materials. These materials will provide basic tips on diet, physical activity and other lifestyle factors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intervention acceptability based on the proportion of sessions attended
Time Frame: 3 months (post intervention)
Acceptability of the intervention will be measured by the number (%) of intervention sessions attended. Each participant will be offered 12 intervention sessions, and the acceptability of the intervention will be measured by the proportion of sessions attended (# sessions attended/ 12).
3 months (post intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in glycemia
Time Frame: 0 and 3 months
Changes in HbA1c at 3 months post baseline.
0 and 3 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weight loss
Time Frame: 0 and 3 months
Mean weight loss at 3 months post baseline.
0 and 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

New York University

Investigators

  • Principal Investigator: Jeannette Beasley, PhD, New York University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

August 1, 2027

Study Registration Dates

First Submitted

January 20, 2026

First Submitted That Met QC Criteria

February 24, 2026

First Posted (Actual)

March 2, 2026

Study Record Updates

Last Update Posted (Actual)

March 2, 2026

Last Update Submitted That Met QC Criteria

February 24, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ADHRTC-2025-195/HRPP-2023-238

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Local data privacy laws may prohibit the public sharing of individual-level participant data. We will share data upon a reasonable request to the study PI.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pre-diabetes

Clinical Trials on Adapted diabetes prevention program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe